Management of Hepatitis B Infection

  • Authors: Harry L. A. Janssen, MD, PhD; Milan J. Sonneveld, MD, PhD, MSc (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 5/25/18 (What's New)


  • Maintenance of undetectable HBV DNA levels is the key on-treatment goal in nucleos(t)ide analogue–treated patients
    • In HBeAg-positive patients, the definitive endpoint for therapy is HBeAg seroconversion. Treatment may be discontinued in patients without cirrhosis who have achieved this endpoint and completed ≥ 12 months of consolidation therapy after the appearance of anti-HBe (Table 9)[Terrault 2018]

      • AASLD recommends indefinite treatment for patients with cirrhosis[Terrault 2018]

Action required